Watchmaker Genomics Raises $40M Series A Financing To Accelerate Growth And Expand Clinical Sequencing Product Offerings
Watchmaker Genomics Raises $40M Series A Financing To Accelerate Growth And Expand Clinical Sequencing Product Offerings
06/02/22, 9:30 AM
Location
boulderMoney raised
$40 million
Industry
other
Round Type
series a
Watchmaker Genomics, a life sciences company specializing in the development of high-stringency applications focused on the reading, writing, and editing of DNA and RNA, today announced it had secured $40 million in an oversubscribed Series A, bringing total funding to date to $53.5 million. The round was led by Decheng Capital, with co-investment from Eclipse Ventures.
Company Info
Location
boulder, colorado, united states
Additional Info
The company launched its first product in 2020 and has since achieved profitability with 175% year-over-year revenue growth. In addition, the company will expand commercial channels and manufacturing capacity, making these product solutions more broadly accessible to the life science and genomics communities. "We are thrilled to partner with Watchmaker Genomics as the company enters its next phase of product innovation and commercialization. "Decheng Capital is a leading investor in life science and sequencing, and we are excited to have the firm lead our Series A. The company combines domain expertise in protein engineering with large-scale enzyme manufacturing to address the demanding quality, performance, and scale requirements of high-growth clinical genomics applications.